You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
中關村(000931.SZ):共31個產品入選《醫保目錄2022年版》

格隆匯2月1日丨中關村(000931.SZ)公佈,近日,國家醫保局、人力資源社會保障部發布《關於印發<國家基本醫療保險、工傷保險和生育保險藥品目錄>的通知》【醫保發〔2023〕5號】,公司全資子公司四環醫藥之控股子公司北京華素及其全資子公司山東華素、四環醫藥之控股子公司多多藥業所屬藥品入選《國家基本醫療保險、工傷保險和生育保險藥品目錄(2022年版)》(簡稱“《醫保目錄2022年版》”),公司共31個產品入選《醫保目錄2022年版》,其中:核心產品富馬酸比索洛爾片、戰略品種鹽酸貝尼地平片和潛力品種鹽酸羥考酮片、鹽酸納洛酮注射液等原進入2021年版國家醫保目錄的產品均繼續入選。

相較公司入選《醫保目錄2021年版》中的藥品相關內容,主要調整情形如下:1、北京華素新上市產品鹽酸羥考酮注射液首次納入《醫保目錄2022年版》;2、多多藥業入選產品中有1個產品調整醫保支付範圍。血塞通注射液:2021版醫保目錄中限二級及以上醫療機構的中風偏癱或視網膜中央靜脈阻塞的患者;2022版醫保目錄中限二級及以上醫療機構;3、山東華素入選產品無變化。

Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
uSMART
Wealth Growth Made Easy
Open Account